Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nintedanib/pirfenidone inhalation - Avalyn Pharma

Next Previous
Drug Profile

Nintedanib/pirfenidone inhalation - Avalyn Pharma

Alternative Names: AP-03

Latest Information Update: 24 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avalyn Pharma
  • Class Acetamides; Anti-inflammatories; Antifibrotics; Esters; Indoles; Piperazines; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors; Fms-like tyrosine kinase 3 inhibitors; Lymphocyte specific protein tyrosine kinase p56(lck) inhibitors; Lyn protein-tyrosine kinase inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Src-family kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Interstitial lung diseases

Most Recent Events

  • 03 Oct 2023 Avalyn Pharma has patents pending for aerosol nintedanib compounds and uses thereof in Europe, USA and Australia
  • 29 Sep 2023 Avalyn Pharma has patent protection for aerosol nintedanib compounds and uses thereof in Canada and Japan
  • 29 Sep 2023 Avalyn Pharma has patent protection for aerosol pirfenidone compounds and uses thereof in USA, Australia, Canada and Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top